1997
DOI: 10.1111/j.1432-2277.1997.tb00927.x
|View full text |Cite
|
Sign up to set email alerts
|

Prevention of graft rejection and graft-versus-host reaction by a novel immunosuppressant, FTY720, in rat small bowel transplantation

Abstract: In the present study, we examined the immunosuppressive effect of a new drug, FTY 720, on small bowel transplantation (SBT) in rats. Grafts from (LEW x BN) F 1-to-LEW rats treated with FTY 720 at 0.5 mg/kg from day 0 to 14 post-SBT survived significantly longer than untreated grafts. In addition, the administration of FTY 720 combined with cyclosporin (CyA; 5 mg/kg per day) had a synergistic effect on allograft survival. The graft-versus-host reaction (GVHR) that occurred in the LEWto-F 1 rats was markedly red… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

2
31
1

Year Published

1999
1999
2008
2008

Publication Types

Select...
10

Relationship

2
8

Authors

Journals

citations
Cited by 26 publications
(34 citation statements)
references
References 13 publications
2
31
1
Order By: Relevance
“…؉ T Cells F TY720 is a potent immunomodulator that has been shown to prolong the survival of solid organ allografts, including skin (1-3), heart (4, 5), liver (6 -10), and small bowel (7,11) in animal models. FTY720 has unique modes of action and shows synergy with cyclosporin and sirolimus in these models (7,12).…”
Section: Sphingosine-1-phosphate Receptor Agonism Impairs the Efficiementioning
confidence: 99%
“…؉ T Cells F TY720 is a potent immunomodulator that has been shown to prolong the survival of solid organ allografts, including skin (1-3), heart (4, 5), liver (6 -10), and small bowel (7,11) in animal models. FTY720 has unique modes of action and shows synergy with cyclosporin and sirolimus in these models (7,12).…”
Section: Sphingosine-1-phosphate Receptor Agonism Impairs the Efficiementioning
confidence: 99%
“…It has also been tested and has been well tolerated in human phase I and phase II trials (39) as chronic immunosuppressive therapy. FTY has also shown GvHDinhibitory activity in a rat model in which spleen cells were transplanted from a parental strain into F 1 rats treated with 200 mg/kg cyclophosphamide (40) and in a rat small-bowel transplant model (41).…”
mentioning
confidence: 99%
“…The novel immunosuppressant, FTY720, 2-amino-2-(2-(4-octylphenyl) ethyl)-1,3-propanediol hydrochloride, was screened from synthesized analogs of ISP-1, which is an immunosuppressive metabolite of Isaria sinclairii (28 -31). The oral administration of FTY720 prolongs allograft survival in experimental organ transplantation without producing any noticeable side effects (31)(32)(33)(34)(35). The action mechanism of orally administered FTY720 to suppress graft rejection is regarded as a significant decrease in the number of blood lymphocytes, especially T cells (36).…”
mentioning
confidence: 99%